• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.

RELATED PRODUCTS

Market and Product Forecasts: Psoriasis - Novel products and current biologics to fuel future market growth Product Image

Market and Product Forecasts: Psoriasis - Novel products and current biologics to fuel future market growth

  • ID: 2013994
  • November 2011
  • 68 pages
  • Datamonitor

Enbrel (etanercept; Amgen/Pfizer) remains the market leader, with 32% of an estimated $4.5bn psoriasis market in 2011. However, Humira (adalimumab; Abbott/Eisai) is closing in, with 29% market share. Still, Stelara (ustekinumab; Janssen Biotech) is trailblazing the US and EU markets, threatening both brands. By 2020, biosimilars, generics and four product launches will grow the market to $5.5bn.

Features and benefits

- Access Datamonitor’s patient based psoriasis market forecast of over 50 products in the seven major markets, with clear methodology and assumptions.
- Assess current and future patient-numbers and enhance understanding of the impact future events may have on these.
- Evaluate which novel products Datamonitor expects to launch over the coming decade, and how each of these will alter the market.
- Gain insight into the psoriasis competitive landscape, and determine which brands drive growth.

Highlights

- Owing to delayed competition from key contender Ozespa (briakinumab; Abbott), a favorable dosing regimen, and expansion into Japan in March 2011, Stelara will continue its ascendance in the seven major psoriasis markets (the US, READ MORE >

Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION
Market definition for psoriasis
Forecast methodology and assumptions
Methodology flow
Patent expiries
New product launches
Additional forecast methodology
MARKET OVERVIEW AND CONTEXT
Current and future market dynamics overview
Novel biologic and oral pipeline therapies set to intensify future competition for key marketed biologics
US market to experience positive growth over the coming decade
Availability of biologics boosts sales in Japanese psoriasis market
Continuing uptake of biologics coupled with new product launches will spur growth in the EU
France
Germany
Italy
Spain
UK
PRODUCT FORECASTS: BIOLOGICS
Enbrel (etanercept; Amgen/Pfizer/Stiefel/Takeda)
Forecast assumptions
Enbrel forecast 2011–
Humira (adalimumab; Abbott/Eisai)
Forecast assumptions
Humira forecast 2011–
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe)
Forecast assumptions
Remicade forecast 2011–
Stelara (ustekinumab; Janssen Biotech/Janssen-Cilag/Johnson & Johnson)
Forecast assumptions
Stelara forecast 2011–
Ozespa (briakinumab/ABT-874; Abbott)
Forecast assumptions
Ozespa forecast 2011–
AIN457 (secukinumab; Novartis)
Forecast assumptions
AIN457 forecast 2011–
PRODUCT FORECASTS: SMALL MOLECULES (TOPICAL)
Dovonex/Daivonex/Psorcutan (calcipotriol; Leo Pharma/Intendis/Torii/Teikoku Medix)
Forecast assumptions
Dovonex/Daivonex/Psorcutan forecast 2011–
Dovobet/Daivobet/Taclonex (calcipotriol and betamethasone; Leo Pharma/Intendis)
Forecast assumptions
Dovobet/Daivobet/Taclonex 2011–
Vectical/Silkis (calcitriol; Galderma)
Forecast assumptions
Vectical/Silkis forecast 2011–
PRODUCT FORECASTS: SMALL MOLECULES (ORAL)
Tofacitinib (formerly tasocitinib, CP-690,550; Pfizer)
Forecast assumptions
Tofacitinib forecast 2011–
Apremilast (CC-10004; Celgene)
Forecast assumptions
Apremilast forecast 2011–
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX
Contributing experts
Forecast methodology
Volume and value forecast methodology
Price and compliance assumptions
Physician sample breakdown
Report methodology

Note: Product cover images may vary from those shown

Our Clients

Our clients' logos